Guggenheim analyst Michael Schmidt raised the firm’s price target on Syndax to $43 from $42 and keeps a Buy rating on the shares after updating the firm’s model to reflect positive pivotal data from the AUGMENT-101 trial. The firm has increased its view on the odds of success for revumenib in r/r KMT2Ar AML and ALL to 95%, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNDX:
- Syndax price target raised to $42 from $38 at H.C. Wainwright
- Syndax announces ‘positive’ results from AUGMENT-101 trial of revumenib
- Syndax put volume heavy and directionally bearish
- Syndax call volume above normal and directionally bullish
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)